We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.75 | -5.88% | 12.00 | 11.50 | 12.00 | 12.75 | 11.75 | 12.75 | 582,013 | 16:35:05 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -1.38 | 45.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/4/2018 10:18 | RNS 20 December 2017 (Final Results to Sept. '17). Post Period Highlights. "Exited administration on 2 November 2017 with a cash balance of GB13.9 million". "....cash runway through to early 2019". Pp. | piperpeter | |
25/4/2018 10:11 | This will go North sharply again today and for the rest of the week. The medium holders will mutlibag. Dont worry about the dips | ernestsyngen | |
25/4/2018 10:06 | Thanks. well done all! | qs99 | |
25/4/2018 09:58 | Obviously, it's the appointment of a new CEO. No position. Wished I had bought at 4p - :( be careful and don't get caught on the spike | mirabeau | |
25/4/2018 09:57 | Anticipation of good results IMO and the new CEO would not have come across unless Redx has a superb future. She has clout and backs winners, just look at her past history . Will be an exciting few months ahead | ernestsyngen | |
25/4/2018 09:55 | Apart from the CEO appointment what is this rise based on please? ta | qs99 | |
25/4/2018 09:53 | Target set at 30p by end of week. My come quicker looking at the buys. By the Summer it could well be up into the late 60'70's IMO | gunwharf2 | |
25/4/2018 09:51 | I will be taking a keen interest in any late declared large buys today. | ernestsyngen | |
25/4/2018 09:46 | Sure is, I wonder if it will go above 30p this afternoon. People taking positions now. The CEO will want to enter with a BANG and that will be good news of sorts | ernestsyngen | |
25/4/2018 09:42 | This is going for a 2nd climb to 30p | 1liam | |
25/4/2018 09:41 | Weak seller out, next stop 175% | cobra786 | |
25/4/2018 09:19 | Now I know talk is cheap....but, as a long suffering holder, I am pleased to see phrases used in the RNS such as 'Lisa has been tasked by the Board to lead the re-launch of the Company and to take the steps necessary to build a substantial biotech company' AND 'I am confident that, as CEO, she is the right person to grow this Company into a very exciting and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.' No guarantees of anything but sounds like there are going to be reasons be cheerful and with someone as well connected as her leading the way, I am much more optimistic for the future. | molatovkid | |
25/4/2018 09:18 | 30p on the chart looks do'able. I think more good news is in the pipe line. Back to the good old days here for investors . Well done all holders and this could be your multibagger of the year! | ernestsyngen | |
25/4/2018 09:15 | Could be today at this rate | cobra786 | |
25/4/2018 09:05 | 30p easy over Coming days | shirley83 | |
25/4/2018 09:00 | ready to explode to 75% + | cobra786 | |
25/4/2018 08:55 | Reputation bounce, or perceived validation of RDX's pipeline or closing of short positions, or all or none of the above. All we can say for certain is that the new CEO would not have done extensive due diligence before joining as she was hardly on a sinking ship beforehand. | mdchand | |
24/4/2018 20:49 | Luckily we have some of these near the bottom. Huge potential ahead . But , wariness needed . Best of All | bbr391 | |
24/4/2018 16:34 | 'The firm is also developing a porcupine drug for conditions such as non-alcoholic steatohepatitis hepatic fibrosis, or NASH for short. It is the pick of a healthy early-stage programme that includes a tie-up with AstraZeneca, details of which are not currently in the public domain.' ...and the new CEO is from AZ, no? She must be privy to the 'tie-up' | tinman | |
24/4/2018 13:02 | www.proactiveinvesto | kamitora | |
24/4/2018 11:31 | She seems well connected and that could be important into the future. One thing is for sure, if she can turn this thing around and build it up from here that will be a job very well done. It's a massive opportunity but not without its downsides. | molatovkid | |
24/4/2018 09:34 | Would like to see the new appt buying in the market before making a judgement on this, but am intrigued why a seasoned corporate would decide to join this minnow at this time. No doubt a large stock option was part of the package but even so, stock options can only be exercised if they're worth something. | mdchand |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions